Non-exclusive Drug Discount Agreement for Budesonide
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Budesonid (ATC-Code nach WHO: A07EA06)
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No guaranteed minimum volumes; actual demand depends on prescription behavior, patient numbers, and pharmacy stockpilin...
Buyer reserves right to terminate Open-House early if exclusive discount agreements are concluded, which typically occu...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Jul 31, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jul 2027
- Non-exclusive drug discount agreements for Budesonide (ATC A07EA06) hard capsules 3 mg
- Open-House model: all interested pharmaceutical companies can participate if they meet conditions
Show full summary
Non-exclusive drug discount agreement under §130a Abs. 8 SGB V for Budesonide (ATC A07EA06) hard capsules 3 mg via Open-House model. Buyer: AOK PLUS for Saxony and Thuringia. No guaranteed volumes; contract ends 31.07.2027. First submission deadline 07.07.2025, later submissions possible. Confidentiality required. Estimated value not disclosed.
Risks
No guaranteed minimum volumes; actual demand depends on prescription behavior, patient numbers, and pharmacy stockpilin...
Buyer reserves right to terminate Open-House early if exclusive discount agreements are concluded, which typically occu...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG with seat in EU/EEA
Eligibility
- Submit exclusion declaration (no grounds under GWB §§123-124) and Russia sanctions declaration
Administrative
- Access and use DTVP project room for documents; maintain confidentiality of documents
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive Drug Discount Agreement for Budesonide
Single lot covering Budesonide hard capsules 3 mg. Open-House model, non-exclusive, no individual negotiations. Supply to AOK PLUS region Saxony/Thuringia. Contract duration until 31.07.2027.
Location
Duration
Category
Award Criteria
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Budesonid (ATC-Code nach WHO: A07EA06)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 04 Jun 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 365261-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No guaranteed minimum volumes; actual demand depends on prescription behavior, patient numbers, and pharmacy stockpilin...
Buyer reserves right to terminate Open-House early if exclusive discount agreements are concluded, which typically occu...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications